Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neuren Pharmaceuticals (NEU) has received a notice of allowance from the European Patent Office for NNZ-2591 until July 2034
  • The product will help treat three debilitating childhood disorders for which there are currently no approved drug therapies
  • Following positive results in mouse models, Neuren recently received Orphan Drug designation from the U.S. Food and Drug Administration
  • Despite this breakthrough Neuren has ended the day slightly down with shares trading for $2.42 apiece

Neuren Pharmaceuticals (NEU) has received a notice of allowance from the European Patent Office for NNZ-2591 until July 2034.

The new patent is titled “Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopment disorders”.

Patents under this same international application have previously been granted in the United States and Japan.

Neuren is developing NNZ-2591 to treat the three debilitating childhood disorders of Phenlan-McDermid, Angelman and Pitt Hopkins syndromes for which there are currently no approved drug therapies.

Each of these disorders are caused by a mutation or deletion in a different gene, however, they all share a similar impairment in the connections and signals between brain cells – which id the target treatment of NNZ-2591.

Following positive results in mouse models, Neuren recently received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for NNZ-2591 in treating these syndromes.

After six weeks of treatment, these mice showed normal results in anxiety, daily living, motor performance and reduced seizures.

In October, Neuren received FDA approval to treat Phelan-McDermid Syndrome and Pitt Hopkins Syndrome.

Phelan-McDermid Syndrome is caused by a deletion or mutation of the 22q13 region of chromosome 22 which is responsible for providing instructions to make protein found in the body’s tissue and brain.

This syndrome is identified by low muscle tones in newborns, delayed or absent speech, epilepsy and motor delays. Disruption of the gene is also thought to be associated with autism.

Research by Neuren estimates that one per cent of people with autism have Phelan-McDermid syndrome which implies that anywhere between 1 in 8000 and 1 in 15,000 have the syndrome.

Pitt Hopkins Syndrome is a rare genetic condition that causes moderate-to-severe intellectual disability and developmental delays, gastrointestinal issues, breathing problems and recurrent seizures.

Neuren is currently undertaking the manufacturing development and non-clinical studies required before submitting an investigational new drug (IND) application to the FDA and starting trials in 2020.

Despite this breakthrough Neuren has ended the day slightly down with shares trading for $2.42 apiece in a $253.5 million market cap.

NEU by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.